ArticleHead & neck2026
Behavioral Risk Factors and Seroprevalence for Human Papillomavirus in Sinonasal Carcinoma: A Multi-Institutional Case-Control Study.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
importanceSinonasal carcinomas are rare but aggressive malignancies. A subset is associated with high-risk HPV, but risk factors for HPV-associated sinonasal carcinoma (HPV-SNC) and HPV-independent disease remain poorly understood.
objectiveTo evaluate behavioral and clinical risk factors, including sexual history and substance use, and HPV antibody seropositivity in patients with HPV-SNC and HPV-independent SNC. DESIGN, SETTING, AND
participantsThis multi-institutional case-case-control study was conducted from 2021 to 2024 at two NCI-designated cancer centers. Fifty-two patients with sinonasal carcinoma were enrolled; 37 completed a survey of demographic, clinical, and behavioral factors (24 HPV-SNC, 13 HPV-independent SNC) and serology was obtained for 36 (24 HPV-SNC, 12 HPV-independent SNC). Control noncancer otolaryngology patients (n = 148) from a recent prior study were matched 4:1. EXPOSURE: Self-reported history of sexual behaviors, substance use, and medical history via electronic survey; serum testing for antibodies to low- and high-risk HPV E6, E7, E1, E2, and L1 oncoproteins using a multiplex bead-based assay. MAIN OUTCOME AND MEASURE: Odds of HPV-SNC or HPV-independent SNC diagnosis in relation to risk factors; differences in HPV seropositivity between groups.
resultsAmong the 37 cancer patients who completed the survey, a history of tonsillectomy was significantly associated with reduced odds of HPV-SNC (OR 0.28, CI 0.09-0.86). No other factors explored (sexual behavior, substance use, or other clinical factors) were associated with HPV-associated SNC and HPV-independent SNC. Seroprevalence of anti-HPV16 E6 was significantly higher among HPV-associated SNC cases than either controls or HPV-independent SNC (45.8% vs. 0% and 13.1%), HPV-16 E6 (18.2% vs. 0% and 4.0%), and HPV-16 early proteins (16.7% vs. 0% and 0%) than HPV-independent SNC patients or controls, respectively. CONCLUSIONS AND RELEVANCE: HPV-SNC exhibits distinct serologic features without clear behavioral risk factors. The protective association of tonsillectomy suggests lymphoid tissue may play a role in HPV-associated sinonasal oncogenesis. In contrast, the absence of identifiable risk factors for HPV-independent SNC highlights the need for further etiologic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.